TICKERNERD
Menu
STTKSTTKHealthcare · Biotechnology

STTK Stock Forecast: Shattuck Labs, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$7.42
+1.37% on the day

The 10 Wall Street analysts covering Shattuck Labs, Inc. hold a median 12-month price target of $15 — +95.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$744.7M
Ticker Nerd rank
76 / 100
Median analyst target
$15
Analysts covering
10
Total return, dividends reinvested
1W
+2.1%
1M
+18.0%
YTD
+103.3%
1Y
+762.8%
From 52W high
−6.3%
From 52W low
+762.8%
$0.86
$7.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Shattuck Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
76 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Quality
82
Value
77
Accruals
61
Revisions
57
Growth
55
Size
49
Issuance
32
Volatility
30

Momentum (99): The shares have been drifting up relative to others.

Volatility (30): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26STTKHigh $18Median $15Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $10Median $15High $18

The green dot is the last close — the median target sits +95.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.MaintainsBuy$18 → $14
24 July 2026JP MorganInitiatesOverweight$10
24 July 2026JP MorganInitiatesOverweight—
20 July 2026Leerink PartnersInitiatesOutperform$16
20 July 2026Leerink PartnersInitiatesOutperform—
9 June 2026CitigroupMaintainsBuy—
9 June 2026CitigroupMaintainsBuy$7.00 → $18
8 June 2026HC Wainwright & Co.ReiteratesBuy$18
8 June 2026HC Wainwright & Co.ReiteratesBuy—
8 June 2026NeedhamMaintainsBuy$14 → $17
8 June 2026NeedhamMaintainsBuy—
5 June 2026CitigroupUpgradeBuy—
5 June 2026CitigroupUpgradeBuy$7.00
8 May 2026WedbushMaintainsOutperform—
27 Apr 2026Cantor FitzgeraldInitiatesOverweight—
20 Apr 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026CitigroupMaintainsNeutral—
6 Mar 2026WedbushMaintainsOutperform—
28 Jan 2026Piper SandlerInitiatesOverweight—
6 Jan 2026CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STTK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

STTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Shattuck Labs, Inc. (STTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.6×

Cheaper than 93% of US stocks

Price / sales
744.7×

Cheaper than 2% of US stocks

Price / book
5.9×

Cheaper than 19% of US stocks

EV / EBITDA
−10.3×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−5570.5%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.2%

Higher than 24% of US stocks

Return on assets
−24.4%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

STTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STTKShattuck Labs, Inc.$744.7M
76
GYREGyre Therapeutics, Inc.$744.7M
39
DRUGBright Minds Biosciences, Inc.$743.9M
44
PHATPhathom Pharmaceuticals, Inc.$750.1M
80
MNPRMonopar Therapeutics, Inc.$755.4M
56
CTMXCytomX Therapeutics, Inc.$726.4M
51
BBOTBridgebio Oncology Therapeutics, Inc.$717.5M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Shattuck Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STTK news & analysis

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

Zacks Investment Research · 13 Aug 2026positive

An article notes that the consensus price target for Shattuck Labs (STTK) implies roughly 85.3% upside potential. It also acknowledges that such price-target metrics are generally not highly effective, but points out that an upward trend in earnings estimate revisions could signal near-term upside for the stock.

Why it matters — STTK watchers would care because the piece highlights a large implied upside from the consensus price target as well as a favourable shift in earnings estimate revisions, both of which are closely followed signals for the stock.

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

The Motley Fool · 24 July 2026positive

Shattuck Labs stock rose nearly 5% on Friday after a Motley Fool article expressed encouragement over the progress of SL-325, the company's lead drug candidate, which is about to enter Phase 2 clinical testing.

Why it matters — The article highlights positive sentiment around SL-325's upcoming Phase 2 trial, which represents a key milestone for Shattuck Labs' pipeline.

FAQ

Frequently asked questions about STTK stock

What is the STTK stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Shattuck Labs, Inc. have a median 12-month price target of $15, with estimates ranging from $10 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STTK stock a buy right now?

Of the 10 analysts covering Shattuck Labs, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Shattuck Labs, Inc. 76 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STTK?

As at 15 Aug 2026, Shattuck Labs, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will STTK stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +95.4% from the last close, and Ticker Nerd's factor model ranks Shattuck Labs, Inc. 76 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STTK stock forecast for 2030?

No analyst covering Shattuck Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $18 over the next 12 months.

How has STTK stock performed over the past year?

Shattuck Labs, Inc. returned +762.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Shattuck Labs, Inc. do?

Shattuck Labs Inc. is a biopharmaceutical company focused on developing novel biologic therapies for cancer and autoimmune diseases.

What is the latest news on STTK?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade". An article notes that the consensus price target for Shattuck Labs (STTK) implies roughly 85.3% upside potential. It also acknowledges that such price-target metrics are generally not highly effective, but points out that an upward trend in earnings estimate revisions could signal near-term upside for the stock.

Company

About Shattuck Labs, Inc.

Shattuck Labs Inc. is a biopharmaceutical company focused on developing novel biologic therapies for cancer and autoimmune diseases. The company's proprietary platform, known as Agonist Redirected Checkpoint (ARC), is designed to harness the immune system's power to fight diseases by engaging both T cells and antigen-presenting cells simultaneously. This dual engagement aims to enhance the immune response against tumors and reduce immunological side effects. Operating within the biotechnology sector, Shattuck Labs Inc. is at the forefront of research and development, emphasizing innovative approaches to treat complex conditions. Its clinical-stage pipeline includes several candidates targeting various cancer types, offering potential advantages over existing therapies. Shattuck Labs emphasizes partnerships and collaborations to advance its therapeutic innovations, making it a significant player in the evolving landscape of immunotherapy development.

CEO Dr. Taylor H. Schreiber M.D., Ph.D. · 40 employees · United States · https://www.shattucklabs.com